HC Wainwright Has Optimistic Outlook of DBVT Q2 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Investment analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of DBV Technologies in a research report issued to clients and investors on Friday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their prior forecast of ($0.13). The consensus estimate for DBV Technologies’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at $0.38 EPS and FY2030 earnings at $1.45 EPS.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.11 million.

A number of other equities analysts also recently weighed in on DBVT. Citizens Jmp boosted their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday. Finally, Guggenheim reaffirmed a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, DBV Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $40.25.

DBV Technologies Stock Down 2.0%

Shares of NASDAQ DBVT opened at $19.47 on Tuesday. DBV Technologies has a twelve month low of $7.53 and a twelve month high of $26.18. The stock’s 50 day moving average price is $20.89 and its 200-day moving average price is $18.89. The company has a market capitalization of $1.08 billion, a PE ratio of -4.37 and a beta of -0.97.

Institutional Investors Weigh In On DBV Technologies

Hedge funds have recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of DBV Technologies in the 4th quarter worth approximately $32,000. New York State Common Retirement Fund bought a new stake in shares of DBV Technologies in the 3rd quarter worth approximately $34,000. Royal Bank of Canada bought a new stake in shares of DBV Technologies in the 4th quarter worth approximately $34,000. GAMMA Investing LLC raised its holdings in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares during the period. Finally, Truvestments Capital LLC raised its holdings in shares of DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after purchasing an additional 1,620 shares during the period. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.